Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Nanobiotix S.A.NASDAQ: NBTX

Accounts Receivables · Q4 FY2025 · quarter ended Dec 2025

Accounts receivables grows 394.4% year over year

Q4 FY2025 accounts receivables of €712K rose 394.4% year over year.

Context

  • Accounts receivables amounted to 6.2% of revenue in FY2025.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
€712K— QoQ
Last fiscal yearDec 2025
€1.85M+189.4% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+394.4%——
1 year+189.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

EUR · from the cash flow

Latest · FY2025
1.85M EUR
Year-over-year change
+189.4%
4-year CAGR
+133.8%

Accounts Receivables vs competitors

How NBTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +189.4% is the 2nd highest of 6, against a peer median of +71.8%.
  • Accounts receivables amounts to 6.2% of revenue for NBTX, versus a peer median of 11.1%.
NBTX Competitors
Accounts Receivables for NBTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KURAKura Oncology, Inc.LTM Mar 2026$39.4M USD+184.4%—55.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$22.74M USD+71.8%+119.7%10.5%
IBRXImmunityBio, Inc.LTM Sep 2026$21.58M USD-22.5%—11.8%
NBTXNanobiotix S.A.FY2025€1.85M EUR+189.4%—6.2%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$582K USD+238.4%+39.6%0.3%
IMMXImmix Biopharma, Inc.LTM Mar 2026$55.2K USD-97.2%——
TYRATyra Biosciences, Inc.LTM Mar 2026$0 USD———
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 USD———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
CADLCandel Therapeutics, Inc.LTM Mar 2026$0 USD———
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding NBTX) —+71.8%+79.6%11.1%

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Depreciation & Amortization1.56M1.5M1.51M1.62M1.5M
Deferred Income Tax00003K
Stock-Based Compensation3.2M3.17M3.3M4.3M3.54M
Change in Working Capital(4.7M)(606K)(367K)131K(3.4M)
Accounts Receivables62K(101K)(806K)(2.07M)1.85M
Inventory00000
Accounts Payables00000
Other Working Capital(4.76M)(505K)439K2.2M(5.25M)
Other Non-Cash Items17.07M15.87M22.78M42.53M(11.1M)
Operating Cash Flow(29.87M)(37.1M)(12.48M)(19.55M)(33.42M)
Capital Expenditures(228K)(92K)(328K)(846K)(546K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(14K)230K(21K)(109K)(40K)
Investing Cash Flow(242K)138K(349K)(955K)(578K)
Debt Repayment(3.74M)(4.74M)(3.62M)(4.16M)38.19M
Common Stock Issued00001.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.44M)(916K)50.39M(980K)(2.31M)
Financing Cash Flow(5.18M)(5.65M)46.77M(5.14M)37.42M
Effect of Forex Changes64K83K(51K)94K(402K)
Net Change in Cash(35.23M)(42.53M)33.9M(25.55M)3.01M
Free Cash Flow(30.1M)(37.2M)(12.8M)(20.4M)(33.97M)

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.